Given the continued clinical benefit from pembrolizumab and silibinin, MET tyrosine kinase inhibitors (e.g., tepotinib or capmatinib) were not initiated, although both are approved in Spain as second-line treatment for metastatic METex14 NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.